Genitourinary Cancer News

A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.

Patients with mild to moderate chronic kidney disease or recipients of kidney transplants are at increased risk for cancer, according to data published in the American Journal of Kidney Disease.

Although much remains unknown about the impact of COVID-19 on people with cancer, the impact on screening is becoming clearer.

Current and extended durations of non-aspirin use appeared associated with an increased risk for fatal renal cell carcinoma, according to study results.

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

A form of the HLA-A gene appeared associated with shorter survival among patients treated with immune checkpoint inhibitors, according to a study published in The Lancet Oncology.

Mark W. Ball, MD, spoke with Healio about an ongoing phase 2 study assessing the use of cytoreductive stereotactic hypofractionated radiotherapy along with ipilimumab and nivolumab in patients with metastatic renal cell carcinoma.

In this video, Sumanta K. Pal, MD, discusses updates from a clinical trial on the use of nivolumab/ipilimumab with and without a probiotic agent in patients with metastatic renal cell carcinoma.

Elizabeth Plimack, MD, MS, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, has been appointed the center’s deputy director.

Use of an immune checkpoint inhibitor within 90 days of radiation therapy did not increase risk for serious adverse events among patients with cancer, according to a pooled analysis of prospective trial data published in JAMA Oncology.